CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing small molecule inhibitors called TRAF-STOPs to target the CD40-CD40L signaling pathway, which plays a significant role in atherosclerosis. The goal is to create an oral drug that effectively reduces atherosclerosis without the side effects associated with long-term immune suppression.
Atherosclerosis, the underlying cause of the majority of cardiovascular diseases, is a lipid driven, inflammatory disease ofthe large arteries.
Despite a 25% relative risk reduction achieved by lipid-lowering treatment, the vast majority ofatherosclerosis induced cardiovascular disease risk remains unaddressed.
Therefore, characterizing mediators of theinflammatory aspect of atherosclerosis is a widely recognized scientific goal with great therapeutic implications.
Blocking theco-stimulatory CD4…
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
